SURGIMAB
SurgiMab’s tumor-targeting fluorescent molecules enable real time visualization of tumor margins and micro-tumors which are invisible to the naked eye.
After injection to the patient, SurgiMab’s lead molecule SGM-101 specifically targets various lesions such as colorectal, pancreas or lung tumors. Surgical navigation then allows tumors to be displayed intra-operatively, allowing complete resection. In case of recurrent cancer, when fibrotic tissue sometimes impairs the surgeon’s vision, it can also help the surgeon preserve important structures.
Intraoperative tumor imaging with SurgiMab’s targeted molecules represents a real-time improvement in the intraoperative differentiation between normal and cancer tissue. It will participate in the new paradigm-shift in cancer surgery: surgeons will improve patient outcome while lowering health-care costs.
SurgiMAb was created in 2011. SGM-101 is currently tested in the clinic in the USA and Europe, including two Phase 3 studies.
SurgiMab is seeking additional financing and/or parners to get to the market.
As opposed to an indiscriminate contrast agent, this ability to specifically highlight malignant tissue during a procedure opens up a broad market in both Fluorescence Guided Surgery and potentially also in cancer screening.
SurgiMab’s technique of intraoperative detection of tumors combines the specificity of monoclonal antibodies and the sensitivity of fluorescent detection. To date SGM-101 is the only cancer-targeting fluorescent molecule with efficacy demonstrated in the clinic for several digestive tumors. Surgeons can rely on fluorescence imaging to assess surgical margins, accurately stage cancer and detect small invisible metastases or to spare normal tissue.
– Therapeutic areas: Oncology, Surgery, Molecular Imaging
– Based in: Montpellier (FRANCE)
– Employees: 1-10
– Created in: 2011
